eXoZymes (NASDAQ:EXOZ) Trading Down 1.6% – Should You Sell?

eXoZymes Inc. (NASDAQ:EXOZ)’s stock price traded down 1.6% on Friday . The company traded as low as $6.85 and last traded at $6.97. Approximately 7,051 shares traded hands during mid-day trading, a decline of 50% from the average daily volume of 14,113 shares. The stock had previously closed at $7.08.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of eXoZymes in a report on Friday, May 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

eXoZymes Stock Performance

The firm has a market capitalization of $64.19 million, a PE ratio of -6.11 and a beta of 2.73. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.03. The business’s 50 day simple moving average is $8.74 and its two-hundred day simple moving average is $9.40.

eXoZymes (NASDAQ:EXOZ) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.28) earnings per share (EPS) for the quarter.

About eXoZymes

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.